TEM,PFE Stock Price and Quote

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Peers: ILMN EXAS GH TXG CRSP PACB NTLA EDIT CDNA TWST

| Held by: ARKK VTI VB ARKG VBK IBB IWP JTEK BAI IWF

Index	-	P/E	-	EPS (ttm)	-1.18	Insider Own	44.64%	Shs Outstand	168.58M	Perf Week	6.12%
Market Cap	14.79B	Forward P/E	-	EPS next Y	-0.19	Insider Trans	-2.09%	Shs Float	96.17M	Perf Month	18.91%
Enterprise Value	15.35B	PEG	-	EPS next Q	-0.18	Inst Own	41.64%	Short Float	25.30%	Perf Quarter	19.43%
Income	-199.73M	P/S	15.54	EPS this Y	51.48%	Inst Trans	10.60%	Short Ratio	2.44	Perf Half Y	80.47%
Sales	951.98M	P/B	47.75	EPS next Y	74.69%	ROA	-16.04%	Short Interest	24.33M	Perf YTD	152.16%
Book/sh	1.78	P/C	50.77	EPS next 5Y	-	ROE	-97.95%	52W High	91.45 -6.91%	Perf Year	83.11%
Cash/sh	1.68	P/FCF	-	EPS past 3/5Y	-37.97% -32.48%	ROIC	-17.32%	52W Low	31.36 171.46%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	39.06% 38.58%	Gross Margin	59.21%	Volatility	7.24% 7.46%	Perf 5Y	-
Dividend TTM	-	EV/Sales	16.13	EPS Y/Y TTM	76.46%	Oper. Margin	-23.80%	ATR (14)	5.30	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.43	Sales Y/Y TTM	59.84%	Profit Margin	-20.98%	RSI (14)	63.52	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.54	EPS Q/Q	93.25%	SMA20	8.51%	Beta	5.07	Target Price	74.83
Payout	-	Debt/Eq	2.76	Sales Q/Q	89.57%	SMA50	25.57%	Rel Volume	0.51	Prev Close	86.38
Employees	2400	LT Debt/Eq	2.73	Earnings	Aug 08 BMO	SMA200	48.06%	Avg Volume	9.97M	Price	85.13
IPO	Jun 14, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.31% 5.67%	Trades		Volume	5,207,009	Change	-1.45%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-02-25	Initiated	H.C. Wainwright	Buy	$90
Apr-21-25	Initiated	BTIG Research	Buy	$60
Feb-25-25	Downgrade	JP Morgan	Overweight → Neutral	$50 → $55
Feb-12-25	Downgrade	William Blair	Outperform → Mkt Perform
Feb-05-25	Resumed	TD Cowen	Buy	$58 → $74
Dec-13-24	Initiated	Wolfe Research	Outperform	$60
Dec-09-24	Initiated	Guggenheim	Buy	$74
Nov-11-24	Downgrade	Stifel	Buy → Hold	$45 → $65
Oct-02-24	Downgrade	BofA Securities	Buy → Neutral	$45 → $60
Aug-12-24	Initiated	Piper Sandler	Neutral	$40
Jul-09-24	Initiated	William Blair	Outperform
Jul-09-24	Initiated	TD Cowen	Buy	$50
Jul-09-24	Initiated	Stifel	Buy	$45
Jul-09-24	Initiated	Needham	Buy	$47
Jul-09-24	Initiated	Morgan Stanley	Overweight	$44
Jul-09-24	Initiated	Loop Capital	Buy	$48
Jul-09-24	Initiated	Longbow	Buy	$48
Jul-09-24	Initiated	JP Morgan	Overweight	$42
Jul-09-24	Initiated	BofA Securities	Buy	$41

Show Previous Ratings

Sep-15-25 08:00AM	Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease (PR Newswire)
Sep-12-25 09:42AM	Tempus AI (TEM) Touches 7-Month High on Pixel FDA Approval (Insider Monkey)
08:43AM	Tempus (TEM) Stock Jumps 13.6%: Will It Continue to Soar? (Zacks)
Sep-11-25 06:26PM	Why Tempus AI Stock Soared Nearly 14% Higher Today (Motley Fool) +13.59%
05:01PM	Northwestern Medicine Integrates Tempus AI's "David" Clinical Assistant into EHR Platform (Insider Monkey)
01:58PM	Loading…
01:58PM	Tempus AI Gains FDA Clearance For Updated Pixel To Boost Accuracy And Efficiency In Cardiac Imaging (Benzinga)
11:11AM	Tempus AI Surges, Flirting With A Profit-Taking Zone, On A Fresh FDA Move (Investor's Business Daily)
08:35AM	TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape (Zacks)
08:30AM	Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device (Business Wire)
Sep-09-25 08:44AM	TEM Q2 Revenues Soar Amid Coverage Issues: Time to Buy, Hold or Sell? (Zacks)
08:30AM	Tempus Announces New Study in JCO Precision Oncology Validating PurIST Algorithm for Enhanced Therapy Selection in Pancreatic Cancer (Business Wire)
Sep-04-25 12:30PM	What's Fueling Tempus AI's Q2 Net Loss Improvement Momentum? (Zacks)
08:30AM	Northwestern Medicine Becomes First Health System to Integrate Tempus' Generative AI Co-Pilot, David, Into Its EHR Platform (Business Wire)
Sep-03-25 04:01PM	Tempus to Participate in Morgan Stanleys 23rd Annual Global Healthcare Conference (Business Wire)
Sep-02-25 10:40AM	3 Heavily Shorted Stocks That Could Prove the Bears Wrong (MarketBeat)
09:45AM	Loading…
09:45AM	Elf Beauty downgraded, Zscaler upgraded: Wall Street's top analyst calls (The Fly)
Aug-29-25 11:42PM	Tempus AI, Inc. (TEM) Expands into Digital Pathology with Paige Acquisition (Insider Monkey)
04:36PM	Tempus AI Stock Required A Tempered Position (Investor's Business Daily)
Aug-27-25 10:44AM	Hims & Hers Scales Growth Through Subscriptions and Care Expansion (Zacks)
Aug-26-25 08:42AM	Tempus' Key Acquisitions Strengthen Its AI Healthcare Leadership (Zacks)
06:00AM	Tempus inks $81M Paige buyout to support AI model development (MedTech Dive)
Aug-25-25 03:00PM	Tempus AI or Butterfly: Which AI Health Tech Stock is a Buy Now? (Zacks) -5.74%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
09:12AM	Zacks Market Edge Highlights: ARKK, Tesla, Palantir Technologies, Robinhood Markets and Tempus (Zacks)
05:02AM	Tempus to acquire AI digital pathology company Paige (Medical Device Network)
12:21AM	TD Cowen Lifts Tempus AI (TEM) Price Target on Genomic Volumes Growth (Insider Monkey)
Aug-23-25 04:00AM	The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode (Motley Fool)
Aug-22-25 02:38PM	Tempus AI Expands Into Digital Pathology With Paige Acquisition (Benzinga)
09:20AM	Tempus Announces the Acquisition of Paige (Business Wire)
08:02AM	4 Medical Devices Behemoths to Buy Amid Extensive AI Applications (Zacks)
07:11PM	Loading…
Aug-21-25 07:11PM	Cathie Wood's ARKK ETF is Back: Buy It or Not? (Zacks)
Aug-20-25 11:47AM	5 High Short-Interest Stocks to Buy Before November (MarketBeat)
Aug-19-25 09:33AM	Strategic Partnerships Power Tempus AI's Healthcare Expansion (Zacks) -6.85%
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +6.33%
Aug-16-25 07:00AM	MarketBeat Week in Review - 08/11 - 08/15 (MarketBeat)
Aug-14-25 02:54PM	Tempus AI Stock Scores Relative Strength Rating Upgrade (Investor's Business Daily)
08:07AM	Webtoon, Carlsberg, Tempus: Trending Stocks (Yahoo Finance Video)
08:00AM	Dow Jones Futures: Is Stock Market Rotating? This Cathie Wood, Nancy Pelosi Pick Is A Buy (Investor's Business Daily)
Aug-13-25 04:39PM	Tempus AI's Strong Q2 Fuels Growth Story-More Upside Ahead? (MarketBeat)
03:00PM	Tempus AI Stock Jumps Post Q2 as EBITDA Breakeven Nears: Buy or Hold? (Zacks)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:37AM	TEM Once Again Raises Its 2025 Sales Guidance: What's Driving the Move? (Zacks)
Aug-11-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-09-25 03:04AM	Tempus AI Inc (TEM) Q2 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Advances (GuruFocus.com)
Aug-08-25 06:42PM	Why Tempus AI Stock Jumped Today (Motley Fool)
12:19PM	Gold hits new high, altcoins stocks rally, Tempus AI Q2 beat (Yahoo Finance Video)
09:30AM	Compared to Estimates, Tempus (TEM) Q2 Earnings: A Look at Key Metrics (Zacks)
08:47AM	TEM's Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market (Zacks)
07:13AM	Tempus AI Raises Outlook, CEO Cites Faster-Than-Expected Growth And Improved Margins (Benzinga)
07:10AM	Tempus AI (TEM) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
06:41AM	Tempus AI shares leap on forecast-beating results, revenue guidance (Investing.com)
06:17AM	Tempus: Q2 Earnings Snapshot (Associated Press Finance)
06:00AM	Tempus Reports Second Quarter 2025 Results (Business Wire)
Aug-07-25 05:35PM	10x Genomics (TXG) Surpasses Q2 Earnings and Revenue Estimates (Zacks) +5.78%
10:51AM	Hims & Hers Redefines Virtual Care With Integrated Tech Platforms (Zacks)
Aug-06-25 04:15AM	If You'd Invested $1,000 in Tempus AI Stock (TEM) 1 Year Ago, Here's How Much You'd Have Today (Motley Fool)
Aug-05-25 04:01PM	Personalis Reports Second Quarter 2025 Financial Results (Business Wire)
09:04AM	Tempus AI Targets Breast Cancer With Expanded Next - AI Platform (Zacks)
Aug-01-25 03:00PM	Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy? (Zacks)
Jul-31-25 10:44AM	TEM Securities Lawsuit Filed Against Tempus AI, Inc. Contact the DJS Law Group to Discuss Your Rights (PR Newswire)
Jul-29-25 10:59AM	The Zacks Analyst Blog Highlights Tempus AI, NVIDIA, AstraZeneca and Novo Nordisk (Zacks) -5.98%
08:43AM	Tempus AI Taps Growing ICI Market With New xM Assay (Zacks)
Jul-28-25 01:30PM	Tempus AI or NVIDIA: Which is the Smarter Bet in AI-Backed Healthcare? (Zacks)
10:30AM	TEM Securities Lawsuit Filed Against Tempus AI, Inc. Contact the DJS Law Group to Discuss Your Rights (PR Newswire)
Jul-23-25 08:44AM	Tempus AI Gains FDA Nod Amid Booming AI ECG Market Momentum (Zacks) +6.19%
Jul-22-25 08:45AM	Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity (PR Newswire) +5.29%
08:30AM	Tempus to Report Second Quarter 2025 Financial Results on August 8 (Business Wire)
Jul-18-25 08:34AM	Do You Believe in the Growth Potential of Tempus AI (TEM)? (Insider Monkey)
Jul-17-25 03:00PM	TEM Shares Surge on New AI Breakthrough: Should Investors Jump In? (Zacks)
09:19AM	Tempus AI, Inc. (TEM) and Personalis Join Forces to Take on Colorectal Cancer (Insider Monkey)
09:00AM	Big Pharma's AI Adoption Is Reaching a Tipping Point Amid Mounting Pressure and Strategic Opportunity, Finds New Report from Define Ventures (PR Newswire)
Jul-16-25 06:35PM	From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine (PR Newswire) +7.30%
08:00AM	Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software (Business Wire)
Jul-15-25 09:20AM	Tempus AI Raises 2025 Financial Outlook: What's Backing It? (Zacks)
Jul-14-25 02:46PM	Jim Cramer Notes Tempus AI is "Losing Money Hand Over Fist" (Insider Monkey)
11:11AM	Tempus AI Expands "Tempus Next" Platform to Improve Breast Cancer Care with AI-Driven Insights. (Insider Monkey)
Jul-10-25 12:00PM	Cathie Wood's ARK Loads Up on Tempus AI, Cuts Roku and Block (GuruFocus.com)
04:00AM	The early winner in the 'Dexit' war for corporate relocations: Nevada (Yahoo Finance)
Jul-09-25 08:55PM	Lightning Round: When it comes to AI, I believe in Nvidia, says Jim Cramer (CNBC TV)
04:00PM	Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients (Business Wire)
Jul-08-25 08:30AM	Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast Cancer (Business Wire)
Jul-07-25 09:55AM	Tempus AI Boosts R&D Efforts Through Wide-Ranging Product Launches (Zacks)
08:27AM	Here's What Boosted Tempus AI (TEM) in Q1 (Insider Monkey)
08:06AM	TEM Securities Lawsuit Filed Against Tempus AI, Inc. Contact the DJS Law Group to Discuss Your Rights (PR Newswire)
Jul-05-25 12:22PM	Why Tempus AI Stock Soared 15.2% in June (Motley Fool)
Jul-04-25 08:43AM	Tempus AI Revenues & Profit Rise: What to Expect Ahead of Q2 Release (Zacks)
Jul-03-25 12:01PM	Hims & Hers Enhances Healthcare Through AI-Driven Personalization (Zacks)
Jul-02-25 10:28AM	Tempus AI (TEM) Falters on $400-Million Debt Issue (Insider Monkey)
08:11AM	What's Fueling Tempus AI's Explosive Sales Growth? (Zacks)
Jun-30-25 10:43PM	Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior Notes (Business Wire) -6.44%
09:50AM	AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway (PR Newswire)
07:00AM	Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense (Business Wire)
02:42AM	Tempus AI's Ambry Genetics Leads with Validated 99.5% Accurate Hereditary Cancer Risk Assessment Tool (Insider Monkey)
Jun-28-25 09:10AM	10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential (Motley Fool)
Jun-27-25 09:15AM	Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last? (Zacks)
Jun-25-25 05:00PM	Ambry Genetics CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer Testing (Business Wire)
10:15AM	Agentic AI Market worth $140.80 billion by 2032- Exclusive Report by MarketsandMarkets (PR Newswire)
Jun-24-25 07:25PM	Tempus AI, Inc. (TEM): A Bull Case Theory (Insider Monkey)
Jun-23-25 03:00PM	TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now? (Zacks)
Jun-20-25 08:41AM	Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building? (Zacks)

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fukushima Ryan	Chief Operating Officer	Sep 02 '25	Sale	75.80	10,000	758,028	135,000	Sep 04 04:15 PM
Epstein David R	Director	Sep 02 '25	Sale	73.64	250	18,410	27,041	Sep 04 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Aug 27 '25	Sale	74.10	332,500	24,637,581	9,207,533	Aug 29 05:13 PM
Leonsis Theodore	Director	Aug 26 '25	Sale	75.83	20,000	1,516,600	66,756	Aug 28 04:15 PM
Eric Lefkofsky	Officer	Aug 27 '25	Proposed Sale	75.90	332,500	25,236,750		Aug 27 04:19 PM
Leonsis Theodore	Director	Aug 26 '25	Proposed Sale	75.83	20,000	1,516,650		Aug 26 01:27 PM
Polovin Andrew	EVP and General Counsel	Aug 19 '25	Sale	74.65	5,398	402,982	132,056	Aug 21 04:15 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Aug 19 '25	Sale	74.65	3,664	273,532	94,115	Aug 21 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Aug 19 '25	Sale	74.65	17,458	1,303,307	2,020,042	Aug 21 04:15 PM
Fukushima Ryan	Chief Operating Officer	Aug 19 '25	Sale	74.65	17,460	1,303,456	839,180	Aug 21 04:15 PM
Rogers James William	Chief Financial Officer	Aug 19 '25	Sale	74.65	7,528	561,994	138,473	Aug 21 04:15 PM
Bartolucci Ryan M	Chief Accounting Officer	Aug 19 '25	Sale	74.65	1,904	142,141	45,895	Aug 21 04:15 PM
Erik Phelps	Officer	Aug 19 '25	Proposed Sale	78.45	3,664	287,441		Aug 20 07:19 AM
Andrew Polovin	Officer	Aug 19 '25	Proposed Sale	78.45	5,398	423,473		Aug 20 07:17 AM
Ryan Fukushima	Officer	Aug 19 '25	Proposed Sale	78.45	17,460	1,369,737		Aug 20 07:15 AM
Eric Paul Lefkofsky	Officer	Aug 19 '25	Proposed Sale	78.45	17,458	1,369,580		Aug 20 07:14 AM
James William Rogers	Officer	Aug 19 '25	Proposed Sale	78.45	7,528	590,572		Aug 19 09:59 PM
Ryan M. Bartolucci	Officer	Aug 19 '25	Proposed Sale	78.45	1,904	149,369		Aug 19 09:56 PM
Leonsis Theodore	Director	Aug 13 '25	Proposed Sale	69.90	44,000	3,075,786		Aug 18 02:44 PM
Leonsis Theodore	Director	Aug 13 '25	Sale	69.90	44,000	3,075,600	86,756	Aug 15 09:21 PM
Epstein David R	Director	Aug 01 '25	Sale	55.16	370	20,409	27,291	Aug 05 04:15 PM
DAVID R. EPSTEIN	Director	Aug 01 '25	Proposed Sale	56.59	620	35,086		Aug 01 04:30 PM
LEFKOFSKY ERIC P	CEO and Chairman	Jul 28 '25	Sale	62.87	166,250	10,452,027	9,274,033	Jul 30 08:42 PM
Eric Lefkofsky	Officer	Jul 28 '25	Proposed Sale	64.49	166,250	10,721,462		Jul 28 04:13 PM
Fukushima Ryan	Chief Operating Officer	Jul 07 '25	Sale	60.00	5,000	300,000	145,000	Jul 09 04:15 PM
VANESSA L KUBO	Officer	Jul 07 '25	Proposed Sale	60.97	20,000	1,219,400		Jul 07 04:16 PM
Doudna Jennifer A	Director	Jul 01 '25	Sale	62.52	625	39,075	26,554	Jul 03 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Jun 17 '25	Sale	70.07	250,000	17,516,593	9,357,283	Jun 20 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Jun 18 '25	Sale	69.44	250,000	17,359,469	9,307,283	Jun 20 04:15 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Jun 16 '25	Sale	72.56	51,317	3,723,634	97,779	Jun 18 04:15 PM
Polovin Andrew	EVP and General Counsel	Jun 16 '25	Sale	72.13	1,423	102,641	137,454	Jun 18 04:15 PM
Eric Paul Lefkofsky	Officer	Jun 17 '25	Proposed Sale	72.00	400,000	28,800,000		Jun 17 09:45 PM
ERIK PHELPS	Officer	Jun 16 '25	Proposed Sale	71.28	51,317	3,657,876		Jun 16 04:30 PM
ANDREW POLOVIN	Officer	Jun 16 '25	Proposed Sale	71.28	1,423	101,431		Jun 16 04:22 PM
Leonsis Theodore	Director	Jun 11 '25	Sale	67.66	205,847	13,927,976	0	Jun 13 04:15 PM
Revolution Growth Management C	Shareholder	Jun 11 '25	Proposed Sale	69.38	205,847	14,281,665		Jun 11 04:02 PM
Fukushima Ryan	Chief Operating Officer	Jun 03 '25	Sale	62.29	20,000	1,245,764	856,640	Jun 05 04:15 PM
Doudna Jennifer A	Director	Jun 02 '25	Sale	55.20	558	30,802	27,179	Jun 04 04:15 PM
Epstein David R	Director	Jun 02 '25	Sale	55.20	250	13,800	27,661	Jun 04 04:15 PM
JENNIFER A DOUDNA	Director	Jun 02 '25	Proposed Sale	55.18	1,183	65,278		Jun 02 04:32 PM
Rogers James William	Chief Financial Officer	May 20 '25	Sale	63.27	23,121	1,462,809	146,001	May 22 08:00 PM
Polovin Andrew	EVP and General Counsel	May 20 '25	Sale	63.43	17,552	1,113,385	138,877	May 22 08:00 PM
Phelps Erik	EVP & Chief Admin & Legal Off	May 20 '25	Sale	63.21	8,415	531,918	149,096	May 22 08:00 PM
LEFKOFSKY ERIC P	CEO and Chairman	May 20 '25	Sale	63.21	16,752	1,058,905	4,878,837	May 22 08:00 PM
Fukushima Ryan	Chief Operating Officer	May 20 '25	Sale	63.21	7,820	494,308	876,640	May 22 08:00 PM
Bartolucci Ryan M	Chief Accounting Officer	May 20 '25	Sale	63.23	6,073	384,023	47,799	May 22 08:00 PM
Ryan M. Bartolucci	Officer	May 20 '25	Proposed Sale	63.74	4,254	271,150		May 21 07:39 PM
Ryan Fukushima	Officer	May 20 '25	Proposed Sale	63.74	7,820	498,447		May 21 07:36 PM
Andrew Polovin	Officer	May 20 '25	Proposed Sale	63.74	9,797	624,461		May 21 07:25 PM
Eric Paul Lefkofsky	Officer	May 20 '25	Proposed Sale	63.74	16,752	1,067,772		May 21 07:23 PM
Erik Phelps	Officer	May 20 '25	Proposed Sale	63.74	8,415	536,372		May 21 07:20 PM
James William Rogers	Officer	May 20 '25	Proposed Sale	63.74	11,413	727,465		May 21 07:18 PM
RYAN BARTOLUCCI	Officer	May 20 '25	Proposed Sale	63.74	1,819	115,943		May 20 04:32 PM
ANDREW POLOVIN	Officer	May 20 '25	Proposed Sale	63.74	7,755	494,304		May 20 04:31 PM
JAMES ROGERS	Officer	May 20 '25	Proposed Sale	63.74	11,708	746,268		May 20 04:31 PM
Leonsis Theodore	Director	May 09 '25	Sale	66.26	770	51,020	43,550	May 13 04:15 PM
REVOLUTION GROWTH III, LP	Shareholder	May 09 '25	Proposed Sale	65.22	770	50,219		May 09 04:18 PM
Fukushima Ryan	Chief Operating Officer	May 06 '25	Sale	52.36	20,000	1,047,239	884,460	May 08 04:30 PM
Epstein David R	Director	May 01 '25	Sale	53.50	370	19,795	25,914	May 05 04:15 PM
Gottlieb Scott	Director	Apr 01 '25	Sale	47.21	27,837	1,314,154	32,839	Apr 03 05:30 PM
Doudna Jennifer A	Director	Apr 01 '25	Sale	48.12	625	30,075	25,740	Apr 03 04:15 PM
Fukushima Ryan	Chief Operating Officer	Apr 01 '25	Sale	47.20	20,000	944,085	904,460	Apr 03 04:15 PM
Frederick Wayne A.I.	Director	Mar 31 '25	Sale	45.54	3,000	136,620	26,514	Apr 02 06:13 PM
RYAN FUKUSHIMA	Officer	Apr 01 '25	Proposed Sale	48.24	60,000	2,894,400		Apr 01 04:22 PM
Polovin Andrew	EVP and General Counsel	Mar 21 '25	Sale	50.00	3,076	153,800	151,095	Mar 25 04:15 PM
ANDREW POLOVIN	Officer	Mar 21 '25	Proposed Sale	48.04	3,076	147,771		Mar 21 04:21 PM
Rogers James William	Chief Financial Officer	Mar 18 '25	Sale	45.97	23,030	1,058,699	164,750	Mar 19 06:30 PM
Polovin Andrew	EVP and General Counsel	Mar 18 '25	Sale	45.98	13,135	603,970	154,171	Mar 19 06:30 PM
Epstein David R	Director	Mar 17 '25	Sale	46.83	990	46,362	26,284	Mar 19 06:30 PM
West Nadja	Director	Mar 17 '25	Sale	48.86	7,634	372,962	30,071	Mar 19 06:30 PM
Gottlieb Scott	Director	Mar 17 '25	Sale	48.85	27,838	1,359,989	60,676	Mar 19 06:30 PM
Frederick Wayne A.I.	Director	Mar 17 '25	Sale	48.85	9,000	439,659	29,514	Mar 19 06:30 PM
Doudna Jennifer A	Director	Mar 17 '25	Sale	48.80	9,308	454,210	26,365	Mar 19 06:30 PM
ANDREW POLOVIN	Officer	Mar 18 '25	Proposed Sale	49.87	13,135	655,042		Mar 18 04:41 PM
JAMES ROGERS	Officer	Mar 18 '25	Proposed Sale	49.87	23,030	1,148,506		Mar 18 04:27 PM
WAYNE FREDERICK	Director	Mar 17 '25	Proposed Sale	47.17	12,000	566,040		Mar 17 04:47 PM
DAVID R. EPSTEIN	Director	Mar 17 '25	Proposed Sale	47.17	1,610	75,944		Mar 17 04:25 PM
SCOTT GOTTLIEB	Director	Mar 17 '25	Proposed Sale	47.17	55,675	2,626,190		Mar 17 04:23 PM
LEFKOFSKY ERIC P	CEO and Chairman	Mar 05 '25	Sale	50.93	562,345	28,641,725	9,457,283	Mar 07 04:56 PM
LEFKOFSKY ERIC P	CEO and Chairman	Mar 06 '25	Sale	49.83	250,000	12,457,454	9,407,283	Mar 07 04:56 PM
Fukushima Ryan	Chief Operating Officer	Mar 04 '25	Sale	51.15	20,000	1,022,974	924,460	Mar 06 05:05 PM
West Nadja	Director	Mar 04 '25	Sale	51.11	809	41,347	37,705	Mar 06 05:05 PM
Eric P. Lefkofsky	Officer	Mar 05 '25	Proposed Sale	52.73	662,345	34,925,452		Mar 05 05:44 PM
Doudna Jennifer A	Director	Mar 03 '25	Sale	57.52	338	19,442	35,673	Mar 05 04:15 PM
Epstein David R	Director	Mar 03 '25	Sale	57.52	250	14,380	27,274	Mar 05 04:15 PM
NADJA WEST	Director	Mar 04 '25	Proposed Sale	50.93	8,443	430,002		Mar 04 05:08 PM
LEFKOFSKY ERIC P	CEO and Chairman	Feb 27 '25	Sale	58.75	3,240,234	190,363,748	0	Feb 27 07:39 PM
Lightbank Investments 1B, LLC	Affiliate	Feb 27 '25	Proposed Sale	59.10	115,751	6,840,884		Feb 27 04:27 PM
Innovation Group Investors, L.	Affiliate	Feb 27 '25	Proposed Sale	59.10	1,580,928	93,432,845		Feb 27 04:26 PM
Lightbank Global, LLC	Affiliate	Feb 27 '25	Proposed Sale	59.10	1,397,589	82,597,510		Feb 27 04:25 PM
Innovation Group Investors, L.	Affiliate	Feb 27 '25	Proposed Sale	59.10	145,966	8,626,591		Feb 27 04:24 PM
LEFKOFSKY ERIC P	CEO and Chairman	Feb 19 '25	Sale	80.87	84,640	6,844,680	4,964,820	Feb 20 07:55 PM
LEFKOFSKY ERIC P	CEO and Chairman	Feb 20 '25	Sale	74.09	69,231	5,129,325	4,895,589	Feb 20 07:55 PM
Fukushima Ryan	Chief Operating Officer	Feb 19 '25	Sale	81.87	2,868	234,814	944,460	Feb 20 07:55 PM
Bartolucci Ryan M	Chief Accounting Officer	Feb 20 '25	Sale	80.00	1,682	134,560	44,500	Feb 20 07:55 PM
Bartolucci Ryan M	Chief Accounting Officer	Feb 19 '25	Sale	81.87	818	66,973	46,182	Feb 20 07:55 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Feb 18 '25	Sale	82.36	61,582	5,072,077	153,080	Feb 20 07:55 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Feb 19 '25	Sale	81.87	903	73,932	152,177	Feb 20 07:55 PM
Polovin Andrew	EVP and General Counsel	Feb 18 '25	Sale	82.32	64,381	5,299,820	172,857	Feb 20 07:55 PM
Polovin Andrew	EVP and General Counsel	Feb 19 '25	Sale	81.87	5,551	454,470	167,306	Feb 20 07:55 PM

Peers: BMY MRK SNY AMGN ABBV NVS JNJ GSK LLY AZN

| Held by: VTI VOO SPY IVV VTV XLV VYM VHT COWZ DVY

Index	S&P 500	P/E	12.74	EPS (ttm)	1.88	Insider Own	0.12%	Shs Outstand	5.68B	Perf Week	-2.36%
Market Cap	136.28B	Forward P/E	7.60	EPS next Y	3.16	Insider Trans	0.00%	Shs Float	5.68B	Perf Month	-4.54%
Enterprise Value	185.15B	PEG	106.18	EPS next Q	0.72	Inst Own	66.97%	Short Float	1.82%	Perf Quarter	-2.32%
Income	10.73B	P/S	2.13	EPS this Y	-0.48%	Inst Trans	-0.69%	Short Ratio	2.49	Perf Half Y	-6.80%
Sales	63.83B	P/B	1.54	EPS next Y	1.95%	ROA	5.08%	Short Interest	103.47M	Perf YTD	-9.65%
Book/sh	15.60	P/C	10.29	EPS next 5Y	0.12%	ROE	12.16%	52W High	30.43 -21.23%	Perf Year	-19.18%
Cash/sh	2.33	P/FCF	10.96	EPS past 3/5Y	-28.65% -13.25%	ROIC	7.34%	52W Low	20.92 14.61%	Perf 3Y	-49.09%
Dividend Est.	1.71 (7.12%)	EV/EBITDA	7.21	Sales past 3/5Y	-7.84% 9.10%	Gross Margin	67.34%	Volatility	1.86% 1.73%	Perf 5Y	-29.60%
Dividend TTM	1.71 (7.13%)	EV/Sales	2.90	EPS Y/Y TTM	511.13%	Oper. Margin	29.60%	ATR (14)	0.47	Perf 10Y	-19.37%
Dividend Ex-Date	Jul 25, 2025	Quick Ratio	0.85	Sales Y/Y TTM	14.72%	Profit Margin	16.81%	RSI (14)	40.88	Recom	2.50
Dividend Gr. 3/5Y	2.49% 2.97%	Current Ratio	1.16	EPS Q/Q	11938.10%	SMA20	-3.66%	Beta	0.50	Target Price	28.50
Payout	119.94%	Debt/Eq	0.70	Sales Q/Q	10.31%	SMA50	-3.26%	Rel Volume	1.22	Prev Close	23.87
Employees	81000	LT Debt/Eq	0.65	Earnings	Aug 05 BMO	SMA200	-3.73%	Avg Volume	41.50M	Price	23.97
IPO	Jan 17, 1944	Option/Short	Yes / Yes	EPS/Sales Surpr.	34.39% 8.06%	Trades		Volume	50,760,176	Change	0.42%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$24
Dec-10-24	Resumed	BofA Securities	Neutral	$29
Nov-15-24	Initiated	Wolfe Research	Underperform	$25
Oct-25-24	Resumed	Citigroup	Neutral	$30
Oct-17-24	Initiated	Bernstein	Mkt Perform	$32
Aug-07-24	Upgrade	Daiwa Securities	Neutral → Outperform
Mar-22-24	Downgrade	Argus	Buy → Hold
Feb-23-24	Initiated	Guggenheim	Buy	$36
Jan-04-24	Downgrade	TD Cowen	Outperform → Market Perform	$32
Oct-20-23	Resumed	UBS	Neutral	$36 → $34
Oct-16-23	Upgrade	Jefferies	Hold → Buy	$38 → $39
Jul-17-23	Reiterated	JP Morgan	Neutral	$45 → $41
Jul-14-23	Initiated	HSBC Securities	Buy	$50
Jun-29-23	Downgrade	Credit Suisse	Outperform → Neutral	$47 → $40
May-11-23	Downgrade	Daiwa Securities	Outperform → Neutral	$38
Mar-06-23	Initiated	Jefferies	Hold	$43
Feb-07-23	Upgrade	Daiwa Securities	Neutral → Outperform	$51
Jan-26-23	Downgrade	UBS	Buy → Neutral	$55 → $47
Jan-17-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$54 → $50
Jan-04-23	Downgrade	BofA Securities	Buy → Neutral	$60

Show Previous Ratings

Sep-15-25 01:07PM	CDC vaccine panel to meet this week: Here's what's at stake (CNBC TV)
10:27AM	CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock? (Zacks)
09:00AM	Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:56AM	COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths (Zacks)
06:55AM	How Bad Is This Sector's Health Scare? (The Wall Street Journal)
01:56PM	Loading…
Sep-13-25 01:56PM	Moderna shares hit a low after report suggests the FDA plans to tie COVID shots to child deaths (FastCompany)
04:00AM	1 Reason Every Investor Should Know About Pfizer (PFE) Stock (Motley Fool)
Sep-12-25 08:14PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
07:55PM	Review & Preview: Waiting for the Rate Cut (Barrons.com)
07:43PM	Drugmakers Fall on Report US to Claim Covid Shot Killed Kids (Bloomberg)
04:21PM	Vaccine Stocks Fall Following Report of Plans to Link Covid Shot With Child Deaths (The Wall Street Journal)
04:00PM	Why Pfizer (PFE) Shares Are Sliding Today (StockStory)
02:56PM	Vaccine Stocks Fall on Reports FDA Will Allege Link Between Covid-19 Shots and Child Deaths (Barrons.com)
02:11PM	Vaccine Stocks Down Following Report of Plans to Link Covid Shot With Child Deaths (The Wall Street Journal)
01:37PM	COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says (MarketWatch)
12:33PM	Loading…
12:33PM	Pfizer, Moderna, BioNTech trade lower amid report of vaccine link to child deaths (Investing.com)
12:11PM	Trump officials to link child deaths to COVID shots, Washington Post reports (Reuters)
11:35AM	Stock Market Today: Investors await opening trade from Gemini, Via, and Legence (TheStreet)
10:38AM	OLMA Stock Soars 47% in September So Far on Second PFE Deal (Zacks)
10:25AM	Pfizer's Late-Stage Pipeline Fuels Long-Term Growth Prospects (Zacks)
09:08AM	BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains? (Zacks)
03:00AM	Pfizer Is Growing More Reliant on Vaccines as Controversies Swirl (Barrons.com)
Sep-11-25 05:45PM	Why Pfizer (PFE) Outpaced the Stock Market Today (Zacks)
12:49PM	Pfizer (PFE) and BioNTech SE Announce Positive Topline Results From an Ongoing Phase 3 Clinical Trial (Insider Monkey)
11:20AM	Pfizer (PFE), Astellas Post Favorable Trial Results for Bladder Cancer Combo (Insider Monkey)
09:52AM	Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold? (Zacks)
04:25AM	Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer (Zacks)
Sep-10-25 03:55PM	China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order (Investor's Business Daily)
12:12PM	Trump's Going After Prescription Drug Ads. What It Means for Pharmaceutical Sales. (Barrons.com)
11:08AM	5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds (Zacks)
11:02AM	Loading…
11:02AM	J&J Gains FDA Approval for Inlexzoh, Strengthens Pipeline Momentum (Zacks)
05:17AM	Pfizer-Olema Collaboration Targets Metastatic Breast Cancer (Insider Monkey)
Sep-09-25 08:00PM	Health Officials Hunt for Cases Connecting Covid Shot and Harm in Pregnant Women (The Wall Street Journal)
06:48PM	A Lyme Disease Vaccines Final Test Results Could Appear By Yearend. (Barrons.com)
11:21AM	Will LLY's Oncology Portfolio Provide Key Diversification Benefits? (Zacks)
08:50AM	Will Merck's Cost Cuts and New Drug Approvals Ease Headwinds? (Zacks)
06:37AM	Crypto Stock Market Gambles Are Paying Off. Why That Luck Won't Last. (Barrons.com)
Sep-08-25 01:41PM	Amid Vaccine Controversy, Pfizer Says New Covid Shots Are Effective (Barrons.com)
10:15AM	Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth? (Zacks)
09:42AM	Investing in Oncology: 3 Cancer Stocks With Promising Pipelines (Zacks)
09:15AM	J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned? (Zacks)
06:45AM	Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula (Business Wire)
Sep-07-25 10:23AM	Pfizer Inc (PFE) Announces New Trial Collaboration With Olema Pharmaceuticals (Insider Monkey)
09:30AM	Is Pfizer a Millionaire Maker? (Motley Fool)
Sep-05-25 12:22PM	Analyst Report: BioNTech SE (Morningstar Research)
10:27AM	Shots Fired! After RFK Jr.'s Senate Grilling, Will Pfizer, Moderna Survive The Battle In D.C.? (Investor's Business Daily)
Sep-04-25 03:00PM	Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity? (Zacks)
07:53AM	2 Top Dividend Stocks to Buy With Less Than $50 (Motley Fool)
06:45AM	3 Things You Need to Know if You Buy Pfizer Today (Motley Fool)
Sep-03-25 11:19AM	Pfizer defends Covid-19 vaccine effectiveness after Trump remarks (CNBC TV)
10:58AM	Pfizer Defends Covid Shot, Says Trump Deserves Nobel Prize (Bloomberg)
10:04AM	J&J Gears Up for Some Key New Drug Approvals and Launches (Zacks)
Sep-02-25 04:25PM	Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
10:18AM	Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path? (Zacks)
09:07AM	Is Pfizer Stock Underperforming the Nasdaq? (Barchart)
04:00AM	How AI advances will shape the drugmaker of the future (Pharma Voice)
03:28AM	Pfizer Inc. (PFE)'s Updated COVID-19 Vaccine COMIRNATY LP.8.1 Gets FDA Approval, Ships Nationwide (Insider Monkey)
03:21AM	3 High-Yield Dividend Stocks You Can Buy in September and Hold Forever (Motley Fool)
Sep-01-25 11:59AM	Pfizer's Golden Cross Signals Strength: How to Play the Stock (Zacks)
06:00AM	Pfizer's 7% Dividend: Income Gem or Value Trap? (Motley Fool)
Aug-31-25 08:40AM	Large-cap biotech is a sector to watch for investors: Analysts (Yahoo Finance)
06:45AM	3 No-Brainer Stocks to Buy Right Now (Motley Fool)
12:10AM	Pfizer (PFE) Announces FDA Approval of sBLA for Pfizer-BioNTech COVID-19 Vaccine (Insider Monkey)
Aug-30-25 08:45AM	4 Dividend Stocks to Double Up on Right Now -- Including United Parcel Service and Pfizer (Motley Fool)
05:45AM	Better High-Yielding Dividend Stock: Realty Income vs. Pfizer (Motley Fool)
Aug-29-25 11:51AM	Boyd Gaming and Shoe Carnival have been highlighted as Zacks Bull and Bear of the Day (Zacks)
Aug-28-25 05:07PM	Inside the Trump Administrations Vaccine Politics (The Wall Street Journal)
12:04PM	FDA Approves Updated COVID-19 Vaccines but With Restrictions (Zacks)
11:13AM	MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate (Zacks)
10:10AM	Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum? (Zacks)
09:22AM	Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds? (Zacks)
07:55AM	FDA approves mRNA vaccines for new Covid-19 season amid political tension (Pharmaceutical Technology)
03:49AM	Analyst Report: Pfizer Inc. (Morningstar Research)
12:47AM	Morgan Stanley Lifts Pfizer (PFE) Price Target, Keeps Equalweight Rating (Insider Monkey)
Aug-27-25 11:35PM	Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q2 (StockStory)
02:30PM	RFK Jr. Makes Good On Promise To End Covid Vaccine Mandate. BioNTech Tumbles. (Investor's Business Daily)
01:56PM	FDA Approves Pfizer Covid Vaccine but Adds Restrictions on Its Use (Barrons.com)
01:42PM	New Covid-19 Boosters Are Coming Soon. Not Everyone Will Be Eligible to Get One. (The Wall Street Journal)
01:30PM	Unusual Put Option Activity in Pfizer Stock - Have Investors Turned Bearish? (Barchart)
12:50PM	Pfizer and BioNTechs COMIRNATY Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19 (Business Wire)
10:05AM	Will Camzyos Strengthen BMY's Cardiovascular Portfolio? (Zacks)
09:45AM	My 3 Favorite Stocks to Buy Right Now (Motley Fool)
08:08AM	LLY vs. PFE: Which Pharma Giant Is the Better Pick for Investors? (Zacks)
Aug-26-25 08:31PM	Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months' (Benzinga)
09:40AM	GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU (Zacks)
Aug-25-25 10:41PM	Asian shares decline following Wall Street's dip (Associated Press Finance)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
01:22AM	Stocks slip on Wall Street after last week's rally (Associated Press Finance)
Aug-23-25 06:45AM	3 Unstoppable Dividend Stocks to Buy Right Now (Motley Fool)
Aug-22-25 04:27PM	Top Analyst Reports for NVIDIA, Cisco & Linde (Zacks)
09:39AM	AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth (Zacks)
09:00AM	Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:43AM	ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth (Zacks)
08:00AM	Investors Crave Long-Term Debt, But Firms Dont Want to Sell (Bloomberg)
04:35AM	My 5 Favorite Stocks to Buy Right Now (Motley Fool)
Aug-21-25 01:14PM	Latest Fed cut signals, pharma relief rally, Apple TV+ price hike (Yahoo Finance Video)
01:04PM	Padcev-Keytruda combo approved for NHS use in mUC (Pharmaceutical Technology)
11:32AM	US-EU trade deal impacts on pharma industry more 'manageable' than expected (Yahoo Finance)
11:21AM	Low Volatility Calls For This Breakout Trade On Pfizer Stock (Investor's Business Daily)

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dolsten Mikael	Former Officer	May 23 '25	Proposed Sale	23.09	59,781	1,380,632		May 23 10:54 AM
Dolsten Mikael	Former Officer	May 05 '25	Proposed Sale	23.87	55,000	1,312,736		May 05 04:45 PM
DAMICO JENNIFER B.	SVP & Controller	Mar 04 '25	Sale	25.93	2,500	64,825	11,850	Mar 06 01:57 PM
DAMICO JENNIFER B.	SVP & Controller	Feb 27 '25	Option Exercise	31.31	22,416	701,845	31,063	Mar 03 05:39 PM
SUSMAN SALLY	Executive Vice President	Feb 27 '25	Option Exercise	31.31	85,182	2,667,048	250,866	Mar 03 05:38 PM
SAHNI PAYAL	Executive Vice President	Feb 27 '25	Option Exercise	31.31	19,054	596,581	44,242	Mar 03 05:38 PM
McDermott Michael	Executive Vice President	Feb 27 '25	Option Exercise	31.31	48,419	1,515,999	122,413	Mar 03 05:37 PM
LANKLER DOUGLAS M	Executive Vice President	Feb 27 '25	Option Exercise	31.31	156,914	4,912,977	309,790	Mar 03 05:37 PM
Fonseca Lidia	Executive Vice President	Feb 27 '25	Option Exercise	31.31	72,629	2,274,014	111,534	Mar 03 05:36 PM
BOURLA ALBERT	Chairman & CEO	Feb 27 '25	Option Exercise	31.31	582,823	18,248,188	931,744	Mar 03 05:36 PM
McDermott Michael	Executive Vice President	Feb 22 '25	Option Exercise	30.17	11,125	335,641	87,636	Feb 25 07:38 PM
DAMICO JENNIFER B.	SVP & Controller	Feb 22 '25	Option Exercise	30.17	8,741	263,716	17,602	Feb 25 07:38 PM
BOURLA ALBERT	Chairman & CEO	Feb 22 '25	Option Exercise	30.17	238,399	7,192,498	570,436	Feb 25 07:06 PM
LANKLER DOUGLAS M	Executive Vice President	Feb 22 '25	Option Exercise	30.17	85,824	2,589,310	232,775	Feb 25 07:05 PM
SAHNI PAYAL	Executive Vice President	Feb 22 '25	Option Exercise	30.17	12,714	383,581	37,099	Feb 25 07:04 PM
SUSMAN SALLY	Executive Vice President	Feb 22 '25	Option Exercise	30.17	63,573	1,917,997	225,184	Feb 25 07:02 PM
BOSHOFF CHRISTOFFEL	President, R&D	Feb 22 '25	Option Exercise	30.17	8,741	263,716	159,085	Feb 25 06:58 PM
BLAYLOCK RONALD E	Director	Feb 13 '25	Buy	25.65	19,457	499,072	27,707	Feb 14 05:16 PM
Gottlieb Scott	Director	Oct 30 '24	Buy	28.24	1,000	28,240	10,000	Oct 31 04:06 PM

TEM

Tempus AI Inc

PFE

Pfizer Inc

Upgrade your FINVIZ experience